New insights into the mechanism of low high-density lipoprotein cholesterol in obesity

Obesity, a significant risk factor for various chronic diseases, is universally related to dyslipidemia mainly represented by decreasing high-density lipoprotein cholesterol (HDL-C), which plays an indispensible role in development of cardiovascular disease (CVD). However, the mechanisms underlying obesity and low HDL-C have not been fully elucidated. Previous studies have focused on the alteration of HDL catabolism in circulation following elevated triglyceride (TG). But recent findings suggested that liver and fat tissue played pivotal role in obesity related low HDL-C. Some new molecular pathways like microRNA have also been proposed in the regulation of HDL metabolism in obesity. This article will review recent advances in understanding of the potential mechanism of low HDL-C in obesity.

[1]  J. Hokanson,et al.  The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. , 2001, The Journal of clinical endocrinology and metabolism.

[2]  I. Gérin,et al.  Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation* , 2010, The Journal of Biological Chemistry.

[3]  Albert K Groen,et al.  Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. , 2006, The Journal of clinical investigation.

[4]  H. Brewer,et al.  Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. , 2003, The American journal of cardiology.

[5]  H. Yoshimatsu,et al.  TNF-α Induces Hepatic Steatosis in Mice by Enhancing Gene Expression of Sterol Regulatory Element Binding Protein-1c (SREBP-1c) , 2007, Experimental biology and medicine.

[6]  M. Linton,et al.  Unique pathway for cholesterol uptake in fat cells. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Muredach P. Reilly,et al.  Inflammation Impairs Reverse Cholesterol Transport In Vivo , 2009, Circulation.

[8]  X. Deng,et al.  Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements. , 2005, The Biochemical journal.

[9]  P. Allhoff,et al.  The Lipid Research Clinics Program Prevalence Study. , 1980, Circulation.

[10]  G. Goossens.  The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance , 2008, Physiology & Behavior.

[11]  Takeshi Kimura,et al.  MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo , 2010, Proceedings of the National Academy of Sciences.

[12]  M. Hayden,et al.  Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo , 2006, Circulation.

[13]  J. Genest,et al.  Effect of Obesity on High‐density Lipoprotein Metabolism , 2007, Obesity.

[14]  M. Reilly,et al.  Adipocyte Modulation of High-Density Lipoprotein Cholesterol , 2010, Circulation.

[15]  E. Navarro,et al.  Medición ultrasonográfica de grasa visceral intraabdominal en hombres obesos. Asociación con alteración de lípidos séricos e insulinemia , 2010 .

[16]  M. Reilly,et al.  Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis , 2005, PLoS medicine.

[17]  C. Suh,et al.  Lipid profiles in untreated patients with rheumatoid arthritis. , 1999, The Journal of rheumatology.

[18]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[19]  X. Deng,et al.  Dysregulation of sterol regulatory element binding protein-1c in livers of morbidly obese women is associated with altered suppressor of cytokine signaling-3 and signal transducer and activator of transcription-1 signaling. , 2010, Metabolism: clinical and experimental.

[20]  K. Moore,et al.  MiR-33 Contributes to the Regulation of Cholesterol Homeostasis , 2010, Science.

[21]  S. Yokoyama,et al.  On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway Published, JLR Papers in Press, November 1, 2004. DOI 10.1194/jlr.M400402-JLR200 , 2005, Journal of Lipid Research.

[22]  M. Hayden,et al.  Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1 Published, JLR Papers in Press, May 1, 2003. DOI 10.1194/jlr.M300110-JLR200 , 2003, Journal of Lipid Research.

[23]  D. Jacobs,et al.  Plasma High‐density Lipoprotein Cholesterol: Association with Measurements of Body Mass The Lipid Research Clinics Program Prevalence Study , 1980, Circulation.

[24]  N. Wong,et al.  Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF alpha and IL-1beta. , 2003, Biochimica et biophysica acta.

[25]  J. Frohlich,et al.  Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. , 1998, Physiological research.

[26]  R. Dell,et al.  Human adipocyte cholesterol. Concentration, localization, synthesis, and turnover. , 1975, The Journal of clinical investigation.

[27]  H. Brewer,et al.  Increasing HDL Cholesterol Levels. , 2004, The New England journal of medicine.

[28]  M. Haas,et al.  Obesity‐related Changes in High‐density Lipoprotein Metabolism , 2008, Obesity.

[29]  P. Wilson,et al.  Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[30]  A. Tall,et al.  Hepatic Scavenger Receptor BI Promotes Rapid Clearance of High Density Lipoprotein Free Cholesterol and Its Transport into Bile* , 1999, The Journal of Biological Chemistry.

[31]  D. Rader,et al.  When HDL gets fat... , 2008, Circulation research.

[32]  Sidney C. Smith.  Multiple risk factors for cardiovascular disease and diabetes mellitus. , 2007, The American journal of medicine.

[33]  C. Schneider.  Lipids in health and disease. , 2010, Molecular nutrition & food research.

[34]  W. Sluiter,et al.  Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism , 1994, European journal of clinical investigation.

[35]  Paul T. Williams.  The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. , 2004, Metabolism: clinical and experimental.

[36]  S. Kihara,et al.  Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[37]  D. Sviridov,et al.  Altered properties of high density lipoprotein subfractions in obese subjects. , 1997, Journal of lipid research.

[38]  Guoxun Chen,et al.  Trace: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition Central Role for Liver X Receptor in Insulin-mediated Activation of Srebp-1c Transcription and Stimulation of Fatty Acid Synthesis in Liver. Recommended Citation , 2022 .

[39]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[40]  X. Deng,et al.  Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat. , 2001, Journal of lipid research.

[41]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001, Circulation.

[42]  N. Shachter.  Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism , 2001, Current opinion in lipidology.

[43]  N. Wong,et al.  Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF α and IL-1β , 2003 .

[44]  M. Hayden,et al.  Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. , 2001, Journal of lipid research.

[45]  B. S. Mohammed,et al.  Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[46]  G. Watts,et al.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. , 2008, The Journal of clinical endocrinology and metabolism.

[47]  R. Gregg,et al.  Characterization of high density lipoprotein binding to human adipocyte plasma membranes. , 1985, The Journal of clinical investigation.

[48]  Thomas D. Giles,et al.  Council on Nutrition, Physical Activity, and Metabolism Statement on Obesity and Heart Disease From the Obesity Committee of the Weight Loss: An Update of the 1997 American Heart Association Scientific Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of , 2006 .

[49]  A. Häkkinen,et al.  Overproduction of large VLDL particles is driven by increased liver fat content in man , 2006, Diabetologia.

[50]  Yi Zhang,et al.  Enhanced Cellular Uptake of Remnant High-Density Lipoprotein Particles: A Mechanism for High-Density Lipoprotein Lowering in Insulin Resistance and Hypertriglyceridemia , 2008, Circulation research.

[51]  Kenneth R Feingold,et al.  Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. , 2003, Journal of lipid research.

[52]  N. Bardeesy,et al.  Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. , 2009, Biochemical and biophysical research communications.

[53]  B. R. Krause,et al.  Adipose tissue and cholesterol metabolism. , 1984, Journal of lipid research.

[54]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[55]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[56]  E. L. Arrese,et al.  Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes , 2007, Molecular and Cellular Biochemistry.

[57]  J. Danesh,et al.  Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies , 2011, The Lancet.

[58]  P. Allhoff,et al.  The Framingham Offspring Study , 1991 .

[59]  S. Kihara,et al.  Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. , 2007, Biochemical and biophysical research communications.

[60]  K. Moore,et al.  MicroRNAs in lipid metabolism , 2011, Current opinion in lipidology.

[61]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[62]  S. Gidding,et al.  Month-to-month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents. , 1998, The Journal of pediatrics.

[63]  S. Grundy,et al.  Influence of Weight Reduction on Plasma Lipoproteins in Obese Patients , 1983, Arteriosclerosis.

[64]  D. Sviridov,et al.  Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects. , 1997, Journal of lipid research.

[65]  Jonathan D. Smith.  Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. , 2010, Journal of clinical lipidology.

[66]  P. Barter,et al.  Hugh sinclair lecture: the regulation and remodelling of HDL by plasma factors. , 2002, Atherosclerosis. Supplements.

[67]  G. Lewis,et al.  The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. , 2002, Journal of diabetes and its complications.

[68]  B. Egan,et al.  Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.

[69]  R. Vigneri,et al.  Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. , 2004, The Journal of clinical endocrinology and metabolism.

[70]  D. Rader,et al.  Molecular regulation of macrophage reverse cholesterol transport , 2007, Current opinion in cardiology.

[71]  A. Tall,et al.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.

[72]  C. Bouchard,et al.  Adipose Tissue Distribution and Plasma Lipoprotein Levels in Obese Women: Importance of Intra‐abdominal Fat , 1989, Arteriosclerosis.

[73]  Jonathan D. Smith.  Dysfunctional HDL as a diagnostic and therapeutic target. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[74]  Costantina Manes,et al.  Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.

[75]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[76]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[77]  Paul Poirier,et al.  Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism , 2006, Circulation.

[78]  G. Lewis,et al.  Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans? Published, JLR Papers in Press, May 9, 2006. , 2006, Journal of Lipid Research.

[79]  J. Kastelein,et al.  A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200 , 2004, Journal of Lipid Research.

[80]  T. Langmann,et al.  High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. , 2007, Biochemical and biophysical research communications.

[81]  S. Kaul,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II , 2001, Circulation.

[82]  R. Rodrigo,et al.  Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. , 2009, Biochimica et Biophysica Acta.

[83]  R. Parker,et al.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.

[84]  R. McPherson,et al.  A Novel Efflux–Recapture Process Underlies the Mechanism of High-Density Lipoprotein Cholesteryl Ester-Selective Uptake Mediated by the Low-Density Lipoprotein Receptor–Related Protein , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[85]  T. Shioda,et al.  MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis , 2010, Science.

[86]  Aaron N. Chang,et al.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. , 2011, The Journal of clinical investigation.

[87]  Jan Nilsson,et al.  Exploiting the Vascular Protective Effects of High-Density Lipoprotein and Its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part I , 2001, Circulation.

[88]  Y. Marcel,et al.  Biochemical and physical properties of remnant-HDL2 and of pre beta 1-HDL produced by hepatic lipase. , 1999, Biochemistry.

[89]  P. Gambert,et al.  Adiponectin Is an Important Determinant of ApoA-I Catabolism , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[90]  D. Stafforini,et al.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.

[91]  N. Wong,et al.  Inhibition of apolipoprotein AI gene expression by tumor necrosis factor alpha: roles for MEK/ERK and JNK signaling. , 2006, Biochemistry.

[92]  M. Hayden,et al.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. , 2005, The Journal of clinical investigation.

[93]  D R Shapiro,et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.

[94]  Christopher P Cannon,et al.  Safety of anacetrapib in patients with or at high risk for coronary heart disease. , 2010, The New England journal of medicine.

[95]  O. Francone,et al.  Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. , 2001, The Journal of clinical investigation.

[96]  D. Rader,et al.  Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. , 2004, The New England journal of medicine.

[97]  S. Kihara,et al.  Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. , 2008, FEBS letters.

[98]  P. Ferré,et al.  Adipocyte cholesterol balance in obesity. , 2004, Biochemical Society transactions.

[99]  T. Saruta,et al.  Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. , 2002, Clinical science.

[100]  M. Cnop,et al.  The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. , 2003, Diabetes.